Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within diabetes care, haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, we employ approximately 42,100 employees in 79 countries, and market our products in more than 170 countries.
Novo Nordisk is controlled by the Novo Nordisk Foundation, enabling long-term planning to do what is best for patients, employees and shareholders
Our B shares are listed on NASDAQ OMX Copenhagen (Novo-B), and our ADRs are listed on the New York Stock Exchange (NVO).
The Triple Bottom Line - our way of doing business
We believe that a healthy economy, environment and society are fundamental to long-term business success. This is why we manage our business in accordance with the Triple Bottom Line business principle and pursue business solutions that maximise value to our stakeholders as well as our shareholders.
In practice, this means that any decision should always seek to combine three considerations: is it financially, socially and environmentally responsible? This way, we continuously optimise our business performance and enhance our contribution to the societies we operate in.
This page is intended for members of the UK public
UK/WB/0515/0012(4) February 2018